Phase 1
N=282
Schools Championing Safe South Africa
Prevention or Reduction of HIV Risk Behavior · Prevention or Reduction of Intimate Partner Violence
Bottom Line
View on ClinicalTrials.gov: NCT05869864 ↗Enrolled (actual)
282
Serious AEs
0.4%
Results posted
Jun 2025
Primary outcome: Primary: Number of Participants Who Expressed Satisfaction With the Intervention — 113 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Schools Championing Safe South Africa (Behavioral)
- Age
- Pediatric · 15+ yrs
- Sex
- Male
- Sponsor
- Brown University
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Expressed Satisfaction With the Intervention |
113 | — |
| PRIMARY Number of Participants Who Were Retained At the 6-month Time Point |
140; 139 | — |
| SECONDARY Prevention or Reduction of Sexual Behavior Related to HIV Acquisition Risk as Measured Through the Percent of Participants Engaged in Lifetime Condom Use. |
95; 92; 98; 99 | — |
| SECONDARY Prevention or Reduction of Attempted or Completed Acts of Intimate Partner Violence Using Mary Koss's Short Form Sexual Violence Perpetration Scale At the 1-month Time Point |
78; 81 | — |
Summary
This study explores the acceptability and feasibility of a school-based intervention called Schools Championing Safe South Africa that engages teachers and students in an integrated approach for preventing risk behavior related to acquisition of HIV and perpetration of IPV among adolescents in South Africa. Teachers and students are agents of change who can transform the school social environment to promote HIV and IPV prevention behaviors for adolescents.
Eligibility Criteria
Inclusion Criteria
- identifies as boy
- 15-17 years of age inclusive
- attends school where study is occurring
Exclusion Criteria
- unable to secure parental consent
- unable to secure parental consent child assent
Data sourced from ClinicalTrials.gov (NCT05869864). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.